Beyond efficacy parity: a novel cost-equilibrium framework for value assessment of competing third-line therapies in metastatic colorectal cancer
BackgroundColorectal cancer remains a leading cause of global cancer mortality, with metastatic CRC (mCRC) requiring sequential therapies after first line treatment failure. While regorafenib and fruquintinib are guideline-endorsed third-line options, their comparative value remains unestablished du...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2025-08-01
|
| Serier: | Frontiers in Pharmacology |
| Fag: | |
| Online adgang: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1606742/full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|